Results 121 to 130 of about 567,668 (313)

Kisspeptin as a test of hypothalamic dysfunction in pubertal and reproductive disorders

Andrology, EarlyView.
Abstract The hypothalamic–pituitary–gonadal axis is regulated by the gonadotropin‐releasing hormone pulse generator in the hypothalamus. This is comprised of neurons that secrete kisspeptin in a pulsatile manner to stimulate the release of GnRH, and, in turn, downstream gonadotropins from the pituitary gland, and subsequently sex steroids and ...
Aureliane C. S. Pierret, Aaran H. Patel, Elisabeth Daniels, Alexander N. Comninos, Waljit S. Dhillo, Ali Abbara   +5 more
wiley   +1 more source

GABA in the Deep Layers of the Superior Colliculus/Mesencephalic Reticular Formation Mediates the Enhancement of Startle by the Dopamine D₁Receptor Agonist SKF 82958 in Rats [PDF]

, 2000
Edward G. Meloni, Michael J. Davis
openalex   +1 more source

Preclinical models for evaluating psychedelics in the treatment of major depressive disorder

British Journal of Pharmacology, EarlyView.
Psychedelic drugs have seen a resurgence in interest as a next generation of psychiatric medicines with potential as rapid‐acting antidepressants (RAADs). Despite promising early clinical trials, the mechanisms which underlie the effects of psychedelics are poorly understood.
Laith Alexander, Dasha Anderson, Luke Baxter, Matthew Claydon, James Rucker, Emma S. J. Robinson   +5 more
wiley   +1 more source

Prenatal Cocaine Exposure Increases Sensitivity to the Attentional Effects of the Dopamine D1 Agonist SKF81297 [PDF]

, 2000
Lorna Elissa Bayer, Alison Brown, Charles F. Mactutus, Rosemarie M. Booze, Barbara J. Strupp   +4 more
openalex   +1 more source

Chiral Cyclic Aliphatic Linkers as Building Blocks for Selective Dopamine D₂ or D₃ Receptor Agonists

, 2021
Francisco O. Battiti, Saheem A. Zaidi, Vsevolod Katritch, Amy Hauck Newman, Alessandro Bonifazi   +4 more
openalex   +2 more sources

The Australia story: Current status and future challenges for the clinical applications of psychedelics

British Journal of Pharmacology, EarlyView.
Abstract The past decade has seen a huge increase in clinical research with psychedelic drugs and 3,4‐methylenedioxymethamphetamine (MDMA), which have revealed great potential for treating mental health conditions. Given this progress in research, as well as the current unmet clinical need of millions of patients, in 2023, the Australian Therapeutic ...
David J Nutt, Peter Hunt, Anne Katrin Schlag, Paul Fitzgerald   +3 more
wiley   +1 more source

Effects of a Dopamine Agonist on the Pharmacodynamics of Levodopa in Parkinson Disease [PDF]

, 2010
Matthew Brodsky, Byung Park, John G. Nutt   +2 more
openalex   +1 more source

Psilocybin as a novel treatment for chronic pain

British Journal of Pharmacology, EarlyView.
Abstract Psychedelic drugs are under active consideration for clinical use and have generated significant interest for their potential as anti‐nociceptive treatments for chronic pain, and for addressing conditions like depression, frequently co‐morbid with pain.
Tate Askey, Reena Lasrado, Maria Maiarú, Gary J. Stephens   +3 more
wiley   +1 more source

Histopathological evaluation of dopamine receptor D2 expression in symptomatic gonadotroph pituitary neuroendocrine tumors: a case series including a rare metastatic case responsive to a dopamine agonist [PDF]

Ken Uekawa, Naoki Shinojima, Takahiro Yamamoto, Shigeo Anai, Kozo Tashima, Motoyuki Igata, Takeshi Matsumura, Rumi Sasaki, Takashi Ohba, Hironori Tashiro, Kazuhito Tanaka, Kentaro Tanaka, Hiroyo Mabe, Shigetoshi Yano, Toshinori Hirai, Yoshiki Mikami, Akitake Mukasa   +16 more
openalex   +1 more source

Conscious perception and the modulatory role of dopamine: no effect of the dopamine D2 agonist cabergoline on visual masking, the attentional blink, and probabilistic discrimination [PDF]

, 2020
Evert Boonstra, Martine R. van Schouwenburg, Anil K. Seth, Markus Bauer, Jasper B. Zantvoord, E. Marleen Kemper, Carien S. Lansink, Heleen A. Slagter   +7 more
openalex   +1 more source